Cargando…
Lipid Nanoparticles as Delivery Vehicles for Inhaled Therapeutics
Lipid nanoparticles (LNPs) have emerged as a powerful non-viral carrier for drug delivery. With the prevalence of respiratory diseases, particularly highlighted by the current COVID-19 pandemic, investigations into applying LNPs to deliver inhaled therapeutics directly to the lungs are underway. The...
Autores principales: | Leong, Ellenmae W. X., Ge, Ruowen |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9496059/ https://www.ncbi.nlm.nih.gov/pubmed/36140280 http://dx.doi.org/10.3390/biomedicines10092179 |
Ejemplares similares
-
Developing inhaled protein therapeutics for lung diseases
por: Matthews, Abigail A., et al.
Publicado: (2020) -
Nanoparticles as delivery vehicles for antiviral therapeutic drugs
por: Maus, Alexander, et al.
Publicado: (2021) -
Lipid-DNA Nanoparticles as Drug-Delivery Vehicles for the Treatment of Retinal Diseases
por: Schnichels, Sven, et al.
Publicado: (2023) -
Nanostructured lipid carriers: versatile oral delivery vehicle
por: Poonia, Neelam, et al.
Publicado: (2016) -
Engineered EV-Mimetic Nanoparticles as Therapeutic Delivery Vehicles for High-Grade Serous Ovarian Cancer
por: Al-Dossary, Amal A., et al.
Publicado: (2021)